Literature DB >> 9582363

Specific inhibition of in vitro formation of protease-resistant prion protein by synthetic peptides.

J Chabry1, B Caughey, B Chesebro.   

Abstract

The transmissible spongiform encephalopathies are characterized by the conversion of the protease-sensitive prion protein (PrPsen) into a protease-resistant isoform (PrPres) associated with the neuropathogenic process in vivo. Recently, PrPres has been shown to be capable of directly inducing the conversion of PrPsen to PrPres in a cell-free in vitro system. In the present experiments, various PrP peptides were studied for their ability to enhance or inhibit this cell-free conversion reaction. None of the synthetic peptides was able to confer protease-resistance to the labeled PrPsen molecules on their own. On the contrary, peptides from the central part of the hamster PrP sequence from 106 to 141 could completely inhibit the conversion induced by preformed PrPres. The presence of residues 119 and 120 from the highly hydrophobic sequence AGAAAAGA (position 113 to 120) was crucial for an efficient inhibitory effect. Fourier transform infrared spectroscopy analysis indicated that inhibitory peptides formed high beta-sheet aggregates under the conditions of the conversion reaction, but this was also true of certain peptides that were not inhibitory. Thus, the potential to form beta-sheeted aggregates may be necessary, but not sufficient, for peptides to act as inhibitors of PrPres formation. Clearly, the amino acid sequence of the peptide is also important for inhibition. The sequence specificity of the inhibition is consistent with the idea that residues in the vicinity of positions 106-141 of PrPres and/or PrPsen are critically involved in the intermolecular interactions that lead to PrPres formation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9582363     DOI: 10.1074/jbc.273.21.13203

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  40 in total

1.  Specific binding of normal prion protein to the scrapie form via a localized domain initiates its conversion to the protease-resistant state.

Authors:  M Horiuchi; B Caughey
Journal:  EMBO J       Date:  1999-06-15       Impact factor: 11.598

2.  Species-independent inhibition of abnormal prion protein (PrP) formation by a peptide containing a conserved PrP sequence.

Authors:  J Chabry; S A Priola; K Wehrly; J Nishio; J Hope; B Chesebro
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

3.  Methods for studying prion protein (PrP) metabolism and the formation of protease-resistant PrP in cell culture and cell-free systems. An update.

Authors:  B Caughey; G J Raymond; S A Priola; D A Kocisko; R E Race; R A Bessen; P T Lansbury; B Chesebro
Journal:  Mol Biotechnol       Date:  1999-11       Impact factor: 2.695

4.  Nucleation-dependent conformational conversion of the Y145Stop variant of human prion protein: structural clues for prion propagation.

Authors:  Bishwajit Kundu; Nilesh R Maiti; Eric M Jones; Krystyna A Surewicz; David L Vanik; Witold K Surewicz
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-30       Impact factor: 11.205

5.  From conversion to aggregation: protofibril formation of the prion protein.

Authors:  Mari L DeMarco; Valerie Daggett
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-24       Impact factor: 11.205

6.  Design and Optimization of Anti-amyloid Domain Antibodies Specific for β-Amyloid and Islet Amyloid Polypeptide.

Authors:  Christine C Lee; Mark C Julian; Kathryn E Tiller; Fanling Meng; Sarah E DuConge; Rehana Akter; Daniel P Raleigh; Peter M Tessier
Journal:  J Biol Chem       Date:  2015-11-24       Impact factor: 5.157

7.  Molecular basis for insulin fibril assembly.

Authors:  Magdalena I Ivanova; Stuart A Sievers; Michael R Sawaya; Joseph S Wall; David Eisenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-28       Impact factor: 11.205

8.  Conservation of a portion of the S. cerevisiae Ure2p prion domain that interacts with the full-length protein.

Authors:  Herman K Edskes; Reed B Wickner
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205

9.  Nonpathogenic Heterologous Prions Can Interfere with Prion Infection in a Strain-Dependent Manner.

Authors:  Alba Marín-Moreno; Patricia Aguilar-Calvo; José Luis Pitarch; Juan Carlos Espinosa; Juan María Torres
Journal:  J Virol       Date:  2018-11-27       Impact factor: 5.103

10.  Motif-grafted antibodies containing the replicative interface of cellular PrP are specific for PrPSc.

Authors:  Gianluca Moroncini; Nnennaya Kanu; Laura Solforosi; Gil Abalos; Glenn C Telling; Mark Head; James Ironside; Jeremy P Brockes; Dennis R Burton; R Anthony Williamson
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.